Postpartum depression pill gets approval in a 1st for Canada

• Biogen's postpartum depression pill has received approval in Canada, marking a significant milestone as it becomes the first medication of its kind authorized in the country. This follows its approval in the United States, the U.K., and the European Union, where it has been available since late 2023.
• The approval of this medication in Canada is a crucial step in addressing postpartum depression, a condition that affects many new mothers. It underscores Biogen's commitment to expanding access to mental health treatments and could lead to improved health outcomes for women experiencing this condition.

— via World Pulse Now AI Editorial System